BioSpace News Archive

INVO Biosciencs, Inc. announced its year end 2017 financial results and recent highlights.

ActoBio Therapeutics have been granted allowance by the U.S. Food and Drug Administration (FDA) for their Investigational New Drug (IND) application to initiate a Phase Ib/IIa study for the treatment of early onset type 1 diabetes (T1D) with AG019.

Addition of new facilities supports strong company-wide growth initiative

Martin Pharmaceuticals, a clinical stage pharmaceutical company focused on repurposing already-approved drugs to offer life-changing advances to patients afflicted with rare (orphan) diseases or challenging medical conditions, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for LIVANTRA™ in the treatment of Acute on Chronic Liver Failure.

JXTG Nippon Oil & Energy Corporation has announced it has agreed to sell Irvine Scientific Sales Company, Inc. and IS Japan Co., Ltd. to FUJIFILM Corporation (FujiFilm).

Aditlys gives patients that are going through dialysis the ability to grow artificial veins using the first polymer-based vascular access solution of this kind

MaxiNovel Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has granted MaxiNovel Orphan Drug Designation for MAX-40279 in the treatment of Acute Myeloid Leukemia (AML).

Seamless payroll integration as a key Sandata differentiator

March 29, 2018 15:45 UTC Pharnext to Present at the H.C. Wainwright Annual Global Life Sciences Conference PARIS--( BUSINESS WIRE )-- Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a c

- Chicago Area Studios Named a Top Contributor for Augie’s Quest During Second Annual Brand-Wide Fundraising Campaign -